# EDGAR Filing Document

**Accession Number:** 0001041024
**File Stem:** 0001628280-26-021176
**Filing Date:** 2026-3
**Character Count:** 27676
**Document Hash:** b5490ea761165ad25ba4f63f898f2d93
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-021176.hdr.sgml**: 20260326

**ACCESSION NUMBER**: 0001628280-26-021176

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260326

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260326

**DATE AS OF CHANGE**: 20260326

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ROCKWELL MEDICAL, INC.
- **CENTRAL INDEX KEY:** 0001041024
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 383317208
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-23661
- **FILM NUMBER:** 26794227

**BUSINESS ADDRESS:**
- **STREET 1:** 30142 WIXOM ROAD
- **CITY:** WIXOM
- **STATE:** MI
- **ZIP:** 48393
- **BUSINESS PHONE:** 8004493353

**MAIL ADDRESS:**
- **STREET 1:** 30142 WIXOM ROAD
- **CITY:** WIXOM
- **STATE:** MI
- **ZIP:** 48393

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ROCKWELL MEDICAL TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 20120530

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ROCKWELL MEDICAL, INC.
- **DATE OF NAME CHANGE:** 20120525

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ROCKWELL MEDICAL TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19970722

?xml version='1.0' encoding='ASCII'? rmti-20260326

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 26, 2026** 

**ROCKWELL MEDICAL, INC.** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-23661** | **38-3317208** |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

**30142 S. Wixom Road, Wixom, Michigan 48393** 

(Address of principal executive offices, including zip code)

**(248) 960-9009** 

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol** | **Name of Each exchange on which registered** |
| Common Stock, par value $0.0001 | RMTI | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

------

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**<u>Item 2.02</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Results of Operations and Financial Condition.</u>**

On March 26, 2026, Rockwell Medical, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated in this Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

**<u>Item 9.01</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Statements and Exhibits.</u>**

(d) Exhibits&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following exhibit is being furnished herewith:

**<u>EXHIBIT INDEX</u>**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press release dated March 26, 2026](a2025q4fy-earningsxpr.htm)</u> |
| 104 | Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101. |

---

------

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **ROCKWELL MEDICAL, INC.** | **ROCKWELL MEDICAL, INC.** |
| Date: March 26, 2026 | By: | /s/ Mark Strobeck |
|  |  | Mark Strobeck |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

![image.jpg](image.jpg)

**Rockwell Medical Announces Fourth Quarter and Full-Year 2025 <br>Financial and Operational Results** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Generated 21% in gross margin for the fourth quarter 2025, representing one of the strongest quarters for gross margin in the Company's history and a meaningful improvement over 15% gross margin for the same period in 2024.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Reported $2.3 million in cash flow from operating activities in the fourth quarter 2025, which increased the Company's cash position at year-end 2025 to $25.0 million.*

**Wixom, Michigan, March 26, 2026** – Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and twelve months ended December 31, 2025.

"2025 was a year of transition for Rockwell Medical. We successfully navigated changes in our customer base, purchase volumes, and distribution footprint, all while maintaining profitability on an Adjusted EBITDA basis for the second consecutive year," said Mark Strobeck, Ph.D., President and CEO of Rockwell Medical. "We made significant changes internally to further align our infrastructure with demand. As a result, our gross margin for the full-year 2025 was in line with gross margin for 2024, and we delivered one of the highest quarterly gross margins in the Company's history in the fourth quarter 2025. Additionally, in the fourth quarter 2025, we generated positive cash flow from operating activities resulting in a higher cash position at year-end. We remain focused on making Rockwell Medical consistently profitable and positioning the Company for long-term stability and success. In 2026, we believe we are well-positioned to build upon this momentum with a clear focus on driving revenue growth, expanding profitability, and further diversifying our portfolio."

**FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL HIGHLIGHTS**

<u>Net Sales</u>

Net sales for the three months ended December 31, 2025 were $18.3 million, compared to net sales of $24.7 million for the same period in 2024. Net sales for the twelve months ended December 31, 2025 were $69.3 million, compared to net sales of $101.5 million for the same period in 2024. The decrease in net sales was driven by a reduction in purchase volume by one of the Company's customers.

<u>Gross Profit</u>

Gross profit for the three months ended December 31, 2025 was $3.9 million, which represents an increase over gross profit of $3.6 million for the same period in 2024. Gross profit for the twelve months ended December 31, 2025 was $11.7 million, compared to gross profit of $17.5 million for the same period in 2024. The decrease in gross profit was driven by a reduction in purchase volume by one of the Company's customers.

------

![image.jpg](image.jpg)

<u>Gross Margin</u>

Gross margin for the three months ended December 31, 2025 was 21%, which represents one of the strongest quarters for gross margin in the Company's history and a meaningful increase over 15% gross margin for the same period in 2024. Gross margin for the twelve months ended December 31, 2025 was 17%, which was in line with the Company's 2025 annual guidance and in line with gross margin for the same period in 2024. In 2025, the Company adjusted its infrastructure and operations to better match demand, with results starting to be reflected in the fourth quarter.

<u>Net Income (Loss)</u>

Net loss for the three months ended December 31, 2025 was $0.6 million, which represents an improvement over a net loss of $0.8 million for the same period in 2024. Net loss for the twelve months ended December 31, 2025 was $5.3 million, compared to a net loss of $0.5 million for the same period in 2024. Net loss for 2025 includes $4.0 million of non-cash depreciation, amortization and stock-based compensation expense, as well as $1.2 million of severance and other costs associated with facility transitions.

<u>Adjusted EBITDA</u>

Rockwell Medical was profitable on an Adjusted EBITDA basis for fourth quarter and full-year 2025. Adjusted EBITDA for the three months ended December 31, 2025 was $1.0 million, compared to Adjusted EBITDA of $1.3 million for the same period in 2024. Adjusted EBITDA for the twelve months ended December 31, 2025 was $0.3 million, in line with the Company's 2025 annual guidance. Adjusted EBITDA for the twelve months ended December 31, 2024 was $5.0 million.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| ***(In Millions, Except Per Share Amounts)*** | **December 31, 2024** | **March 31, 2025** | **June 30, 2025** | **September 30, 2025** | **December 31, 2025** |
| **Net Sales** | $24.7 | $18.9 | $16.1 | $15.9 | $18.3 |
| **Gross Profit** | $3.6 | $3.0 | $2.5 | $2.3 | $3.9 |
| **Gross Margin** | 15% | 16% | 16% | 14% | 21% |
| **Net Income (Loss)** | $(0.8) | $(1.5) | $(1.5) | $(1.8) | $(0.6) |
| **Adjusted EBITDA\*** | $1.3 | $(0.4) | $(0.2) | $0.1 | $1.0 |
| **Basic and Diluted Net Loss per Share \*\*** | $(0.02) | $(0.04) | $(0.05) | $(0.05) | $(0.01) |
| **Adjusted EPS \*** | $0.04 | $(0.01) | $(0.01) | $(0.05) | $0.02 |

---

------

![image.jpg](image.jpg)

---

| | | | |
|:---|:---|:---|:---|
| ***(In Millions, Except Per Share Amounts)*** | **2023** | **2024** | **2025** |
| **Net Sales** | $83.6 | $101.5 | $69.3 |
| **Gross Profit** | $8.7 | $17.5 | $11.7 |
| **Gross Margin** | 10% | 17% | 17% |
| **Net Income (Loss)** | $(8.4) | $(0.5) | $(5.3) |
| **Adjusted EBITDA\*** | $(3.9) | $5.0 | $0.3 |
| **Basic and Diluted Net Loss per Share \*\*** | $(0.37) | $(0.03) | $(0.15) |
| **Adjusted EPS \*** | $(0.17) | $0.16 | $0.01 |

---

 *\* See reconciliation to GAAP financial measures in the tables below.*

*\*\* See Note 3 for more details related to Basic and Diluted Weighted Average Shares Outstanding in our 2025 Form 10-K.* 

<u>Cash and Cash Equivalents and Investments Available-for-Sale</u>

Cash and cash equivalents and investments available-for-sale increased to $25.0 million at December 31, 2025 compared to cash and cash equivalents and investments available-for-sale of $21.6 million at December 31, 2024.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***(In Millions)*** | **December 31, 2024** | **March 31, 2025** | **June 30, 2025** | **September 30, 2025** | **December 31, 2025** |
| **Cash and Cash Equivalents and Investments Available-for-Sale** | $21.6 | $17.3 | $18.4 | $23.7 | $25.0 |

---

**FOURTH QUARTER AND FULL-YEAR 2025 OPERATING HIGHLIGHTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In December 2025, we extended our Amended and Restated Products Purchase Agreement (the "Amended Agreement") dated September 18, 2023 with one of the largest dialysis providers in the United States through December 31, 2026. As part of the Amended Agreement, product pricing will be increased for the extended term.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In November 2025, Joe Dawson was appointed to the Company's board of directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In November 2025, Rashad Brown was named Vice President, Manufacturing and Supply Chain.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the fourth quarter of 2025, we added 30 new customers in the western portion of the United States. With our expanded distribution capabilities, we are now a viable alternative supplier in the western U.S. and are able to more efficiently deliver hemodialysis concentrates products to our existing customers with facilities in that region. The western U.S. now accounts for more than 10% of our customer clinic footprint.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In September 2025, Heather Hunter was promoted to Chief Operating Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In July 2025, Rockwell Medical signed a multi-year product purchase agreement with Innovative Renal Care, one of the largest dialysis service providers in the United States.

------

![image.jpg](image.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In February 2025, Rockwell Medical added a single-use bicarbonate cartridge to its hemodialysis concentrates product portfolio that is 510(k) approved by the U.S. Food and Drug Administration and comes in two sizes, 720 grams and 900 grams.

**GUIDANCE**

For the third year in a row, Rockwell Medical's annual performance was directly in line with its annual guidance. In 2025, Rockwell Medical's achieved net sales, gross margin and Adjusted EBITDA as follows:

---

| | | |
|:---|:---|:---|
| | **2025 Annual Guidance** | **2025 Actual** |
| **Net Sales** | $65.0M to $70.0M | $69.3M |
| **Gross Margin** | 16% to 18% | 17% |
| **Adjusted EBITDA** | ($0.5)M to $0.5M | $0.4M |

---

In 2026, we are working to drive sustainable, profitable growth by adding new customers and renewing contracts with existing customers, improving price and product mix, further enhancing operational efficiencies, and selectively expanding our portfolio through disciplined partnership and business development.

The Company projects its 2026 annual guidance as follows:

---

| | |
|:---|:---|
| | **2026 Annual Guidance** |
| **Adjusted EBITDA** | $1 million to $2 million |
| **Operating Cash Flow** | Positive |

---

Rockwell Medical is currently in negotiations with several large customers, which have the potential to positively impact the Company's net sales and gross margin in 2026. Subsequent to the resolution of those discussions, the Company plans to provide updated annual guidance that also includes net sales and gross margin.

**CONFERENCE CALL AND WEBCAST DETAILS**

**Date:** Thursday, March 26, 2026

**Time:** 8:00am ET

**Live Webcast and Replay:** www.RockwellMed.com/Results

**Speakers:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Mark Strobeck, Ph.D. — President and Chief Executive Officer

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Jesse Neri — SVP, Chief Financial Officer

**Format:** Discussion of fourth quarter and full-year 2025 financial and operational results followed by Q&A.

------

![image.jpg](image.jpg)

**NON-GAAP FINANCIAL MEASURES**

To supplement Rockwell Medical's unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"), this press release also includes references to Adjusted EBITDA, a non-GAAP financial measure that is defined as net income (loss) before net interest income (expense), net other income (expense), income tax expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, and other items that are considered unusual or not representative of underlying trends of our business, including but not limited to one-time severance costs, deferred revenue and inventory reserve amounts, if applicable for the periods presented. The Company has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

Adjusted EBITDA is a key measure used by Rockwell Medical to understand and evaluate operating performance and trends, to prepare and approve its annual budget and to develop short- and long-term operating plans. The Company provides Adjusted EBITDA because it believes the metric is helpful in highlighting trends in its operating results because it excludes items that are not indicative of Rockwell Medical's core operating performance. In particular, the Company believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of Rockwell Medical's business. We believe that Adjusted EBITDA is our best proxy for cash burn.

Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. When evaluating the Company's performance, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and other GAAP results.

**About Rockwell Medical**

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient's home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work<sup>®</sup> four years in a row (2023-2026) and named Fortune Best Workplaces in Manufacturing & Production™ in 2024 and 2025, Rockwell Medical is *Driven to Deliver Life-Sustaining Dialysis Solutions™*. For more information, visit www.rockwellmed.com.

------

![image.jpg](image.jpg)

**Forward-Looking Statements** 

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," "remain steadfast," "guidance," "working to," "goal" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. Such statements include statements relating to: building on our recent momentum with a focus on driving revenue growth, expanding profitability, and further diversifying our portfolio; plans to enhance revenue; expectations for enhancing profitability; intentions regarding advancing portfolio diversification; expected improvement to financial performance from completed infrastructure and operations adjustments; how we plan to drive sustainable and profitable growth; 2026 financial guidance, including Adjusted EBITDA and operating cash flow; and the impact of the outcome of discussions with potential customers. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2025, as such description may be amended or updated in any subsequent reports filed with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

**###**

**CONTACT:** 

(248) 432-1362

IR@rockwellmed.com

*Financial Tables Follow*

**###**

------

![image.jpg](image.jpg)

---

| | | |
|:---|:---|:---|
| **ROCKWELL MEDICAL, INC. AND SUBSIDIARIES** | **ROCKWELL MEDICAL, INC. AND SUBSIDIARIES** | **ROCKWELL MEDICAL, INC. AND SUBSIDIARIES** |
| **CONDENSED CONSOLIDATED BALANCE SHEETS** | **CONDENSED CONSOLIDATED BALANCE SHEETS** | **CONDENSED CONSOLIDATED BALANCE SHEETS** |
| **(Dollars In Thousands)** | **(Dollars In Thousands)** | **(Dollars In Thousands)** |
| | **December 31,** | **December 31,** |
|  | **2025** | **2024** |
| Cash, Cash Equivalents & Investments available-for-sale | $24997 | $21602 |
| Total Assets | $57144 | $59208 |
| Total Liabilities | $20164 | $26620 |
| Total Stockholders' Equity | $36981 | $32588 |
| Common Stock Outstanding | 39405302 | 34056920 |
| Common stock and common stock equivalents\* | 49945902 | 41903896 |
| \*Common stock and common stock equivalents: |  |  |
| Common stock | 39405302 | 34056920 |
| Preferred stock converted | 1405001 | 1391045 |
| Options to purchase common stock | 3276564 | 1886247 |
| Restricted stock awards | 891 | 891 |
| Restricted stock units | 1156660 | 584309 |
| Restricted stock units - Market Condition | 717000 |  |
| Common stock warrants | 3984484 | 3984484 |
| &nbsp;&nbsp;Total common stock and common stock equivalents | 49945902 | 41903896 |

---

------

![image.jpg](image.jpg)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **ROCKWELL MEDICAL, INC. AND SUBSIDIARIES** | **ROCKWELL MEDICAL, INC. AND SUBSIDIARIES** | **ROCKWELL MEDICAL, INC. AND SUBSIDIARIES** | **ROCKWELL MEDICAL, INC. AND SUBSIDIARIES** | **ROCKWELL MEDICAL, INC. AND SUBSIDIARIES** |
| **UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS** | **UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS** | **UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS** | **UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS** | **UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS** |
| ***(In Thousands, Except Shares and Per Share Amounts)*** | ***(In Thousands, Except Shares and Per Share Amounts)*** | ***(In Thousands, Except Shares and Per Share Amounts)*** | ***(In Thousands, Except Shares and Per Share Amounts)*** | ***(In Thousands, Except Shares and Per Share Amounts)*** |
| | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2024** | **Twelve Months Ended December 31, 2025** | **Twelve Months Ended December 31, 2024** |
| Net Sales | $18345 | $24665 | $69258 | $101489 |
| Cost of Sales | 14468 | 21034 | 57563 | 84005 |
| Gross Profit | 3877 | 3631 | 11695 | 17484 |
| Research and Product Development |  | 1 |  | 19 |
| Selling and Marketing | 540 | 843 | 2354 | 2749 |
| General and Administrative | 3736 | 3305 | 14032 | 14108 |
| **Operating Income (Loss)** | **(399)** | **(518)** | **(4691)** | **608** |
| **Other (Expense) Income** |  |  |  |  |
| Realized Gain on Investments | 86 | 23 | 267 | 74 |
| Interest Expense | (286) | (289) | (1124) | (1254) |
| Interest Income | 45 | 29 | 234 | 92 |
| **Total Other Expense** | **(155)** | **(237)** | **(623)** | **(1088)** |
| **Net Income (Loss)** | $**(554)** | $**(755)** | $**(5314)** | $**(480)** |
| **Basic Net Income (Loss) per Share** | $**(0.01)** | $**(0.02)** | $**(0.15)** | $**(0.03)** |
| **Diluted Net Income (Loss) per Share** | $**(0.01)** | $**(0.02)** | $**(0.15)** | $**(0.03)** |
| **Basic Weighted Average Shares Outstanding** | **39405302** | **31551805** | **35974231** | **31058539** |
| **Diluted Weighted Average Shares Outstanding** | **39405302** | **32420168** | **35974231** | **31058539** |

---

------

![image.jpg](image.jpg)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation to GAAP Financial Measures** | **Reconciliation to GAAP Financial Measures** | **Reconciliation to GAAP Financial Measures** | **Reconciliation to GAAP Financial Measures** | **Reconciliation to GAAP Financial Measures** |
| **(In Thousands, Except Shares and Per Share Amounts)** | **(In Thousands, Except Shares and Per Share Amounts)** | **(In Thousands, Except Shares and Per Share Amounts)** | **(In Thousands, Except Shares and Per Share Amounts)** | **(In Thousands, Except Shares and Per Share Amounts)** |
| | **Three Months Ended** | **Three Months Ended** | **Twelve Months Ended** | **Twelve Months Ended** |
| | **December 31** | **December 31** | **December 31** | **December 31** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net Income (Loss) | $(554) | $(755) | $(5314) | $(480) |
| Income taxes |  |  |  |  |
| Other Expense, net | 155 | 237 | 622 | 1088 |
| Depreciation and amortization | 543 | 541 | 2184 | 2174 |
| **EBITDA** | **144** | **23** | **(2508)** | **2782** |
| Severance costs | 112 | 15 | 541 | 24 |
| Stock-based compensation | 456 | 383 | 1816 | 1292 |
| Facility transition | 255 | 886 | 635 | 886 |
| Deferred license revenue |  | (11) | (325) | (46) |
| Triferic inventory write-off |  |  | 178 | 46 |
| **Adjusted EBITDA** | $**967** | $**1295** | $**337** | $**4985** |
| **Adjusted EPS** | $**0.02** | $**0.04** | $**0.01** | $**0.16** |
| **Basic Weighted Average Shares Outstanding** | **39405302** | **31551805** | **35974231** | **31058539** |

---

<br>